Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York98
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT05924750RecruitingPhase 1
Testing a CD33-targeted drug for difficult AML
This Phase 1 trial tests BL-M11D1, a drug designed to target CD33 found on certain AML cells, in adults whose AML has come back or is hard to treat. If you qualify, you may be offered early access to a potential new option while researchers closely monitor safety and side effects.
Hefei, AnhuiAges 18–75 - NCT06285825RecruitingPhase 2
Study of emapalumab for low blood counts after CAR T-cell therapy
This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.
Houston, TexasAges 18 years+ - NCT06285890RecruitingPhase 1
HC-7366 study for relapsed or refractory AML
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
Houston, TexasAges 18 years+ - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT06275555Recruiting
Bivalirudin for blood thinning in ECMO patients
This trial tests if bivalirudin is a safe and effective blood thinner for people on ECMO, a machine that helps your heart and lungs. You may be eligible if you need this therapy and have no past reactions to similar medicines.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06291987RecruitingPhase 1
Ivosidenib with ruxolitinib for advanced MPN with IDH1 mutation
This trial tests a combination of two targeted drugs, ivosidenib and ruxolitinib, for people with advanced myeloproliferative neoplasms (MPNs) that have an IDH1 gene mutation. The goal is to see if this treatment can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT06284486RecruitingPhase 1/Phase 2
Venetoclax and revumenib for AML with residual disease
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
Baltimore, MarylandAges 12 years+ - NCT06290401Recruiting
Boosting self-management in teens with sickle cell disease
This study is testing a program to help adolescents with sickle cell disease better manage their health. It looks at how family, friends, and the clinic can support teens to take charge of their care.
Wilmington, DelawareAges 13–21 - NCT06279013Recruiting
Phone check-ins to manage symptoms during oral cancer treatment
This study tests two ways of using telephone check-ins to help people manage side effects and emotional distress while taking oral anti-cancer pills at home. If you are starting or recently started an oral anti-cancer drug, you may be able to join.
Phoenix, ArizonaAges 18 years+ - NCT06292741Recruiting
Autonomic system test in people with memory loss
This study tests how the body's automatic functions (like heart rate and blood pressure) change in people with mild memory loss. It may help find early signs of nervous system problems.
Rome, LazioAges 50–85 - NCT06287229RecruitingPhase 1/Phase 2
CAR T therapy for B-cell ALL after initial treatment
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
Houston, TexasAges 18 years+ - NCT06280924Recruiting
Exercise before or after stem cell transplant for multiple myeloma
This study tests whether a 10-week exercise program (prehab) before or after a stem cell transplant can help people with multiple myeloma feel stronger and recover better. You can join whether you are getting a transplant or not, as long as you live in Alberta and have internet access.
Edmonton, AlbertaAges 18 years+ - NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+ - NCT06289673RecruitingPhase 4
Collecting info to start treatment for new leukemia or lymphoma
This study gathers key health information at the start of treatment for children and teens newly diagnosed with certain types of leukemia or lymphoma. The goal is to find the best way to begin therapy right away, without waiting for extra tests.
San Diego, CaliforniaAges 1–18 - NCT06291025Recruiting
Testing a simpler treatment for immune-mediated TTP
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
AmiensAges 18 years+ - NCT06287528RecruitingPhase 1
CAR T‑cell therapy with IL‑18 for returning B‑cell leukemia
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
Basking Ridge, New JerseyAges 17 years+ - NCT06292715Recruiting
Spleen shrinking procedure for severe hypersplenism
This trial tests a procedure that uses heat or cold to shrink part of the spleen and block some of its blood supply, which may improve low blood counts caused by cirrhosis-related hypersplenism. It is for patients whose low white blood cells or platelets have not improved with medicine.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06287619RecruitingPhase 2
IV iron after heart surgery for iron deficiency
This trial tests whether giving iron through a vein after heart surgery can help fix low iron levels and improve recovery. It is for people who have iron deficiency (with or without anemia) before their planned heart surgery.
Kingston, OntarioAges 18 years+ - NCT05805202Recruiting
Study rare gene changes in atypical HUS for tailored care
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
Ranica, BGAges Any age - NCT06253507Enrolling by invitationPhase 1/Phase 2
Gene Therapy for Chronic Granulomatous Disease
This study tests a new gene therapy for people with a rare immune disorder called chronic granulomatous disease (CGD), which causes repeated infections. The treatment uses a modified virus to deliver a healthy gene to your blood stem cells, potentially helping your immune system fight off bacteria and fungi. The goal is to reduce the risk of severe infections and improve overall health.
Bethesda, MarylandAges 3–65 - NCT06262789Recruiting
Returning to work after blood cancer treatment
This study helps people who have finished treatment for a blood cancer (like leukemia or lymphoma) figure out the best way to return to work. It looks at what support might be needed during this transition.
AngersAges 18–55 - NCT06270498RecruitingPhase 4
Oral iron for heart failure: exercise and quality of life study
This study tests whether an oral iron supplement (a pill called sucrosomial iron) can help people with heart failure who have low iron feel better, have more energy, and walk farther. Participants will take the iron pill or a placebo (a pill without the active ingredient) for a period and will do exercise tests and answer questionnaires to see how they improve.
Pisa, TuscanyAges 18 years+ - NCT06252792Recruiting
Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Changchun, JilinAges 18 years+ - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,384 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.